.

Make Better Decisions

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Argus Health
Mallinckrodt
UBS
Express Scripts
Chubb
Julphar
Johnson and Johnson
Moodys
Farmers Insurance
Covington

Generated: November 20, 2017

DrugPatentWatch Database Preview

OTREXUP Drug Profile

« Back to Dashboard

Which patents cover Otrexup, and when can generic versions of Otrexup launch?

Otrexup is a drug marketed by Antares Pharma Inc and is included in one NDA. There are thirteen patents protecting this drug.

This drug has thirty-four patent family members in twelve countries.

The generic ingredient in OTREXUP is methotrexate. There are twenty drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the methotrexate profile page.
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Antares Pharma Inc
OTREXUP
methotrexate
SOLUTION;SUBCUTANEOUS204824-003Oct 11, 2013RXYesNo► Subscribe► SubscribeY ► Subscribe
Antares Pharma Inc
OTREXUP PFS
methotrexate
SOLUTION;SUBCUTANEOUS204824-013May 31, 2017RXYesNo► Subscribe► Subscribe► Subscribe
Antares Pharma Inc
OTREXUP
methotrexate
SOLUTION;SUBCUTANEOUS204824-002Oct 11, 2013RXYesNo► Subscribe► SubscribeY ► Subscribe
Antares Pharma Inc
OTREXUP
methotrexate
SOLUTION;SUBCUTANEOUS204824-006Mar 24, 2016RXYesNo► Subscribe► SubscribeY ► Subscribe
Antares Pharma Inc
OTREXUP
methotrexate
SOLUTION;SUBCUTANEOUS204824-004Oct 11, 2013RXYesYes► Subscribe► SubscribeY ► Subscribe
Antares Pharma Inc
OTREXUP
methotrexate
SOLUTION;SUBCUTANEOUS204824-007Mar 24, 2016RXYesNo► Subscribe► SubscribeY ► Subscribe
Antares Pharma Inc
OTREXUP
methotrexate
SOLUTION;SUBCUTANEOUS204824-003Oct 11, 2013RXYesNo► Subscribe► SubscribeY ► Subscribe
Antares Pharma Inc
OTREXUP
methotrexate
SOLUTION;SUBCUTANEOUS204824-002Oct 11, 2013RXYesNo► Subscribe► SubscribeY ► Subscribe
Antares Pharma Inc
OTREXUP PFS
methotrexate
SOLUTION;SUBCUTANEOUS204824-014May 31, 2017RXYesNo► Subscribe► Subscribe► Subscribe
Antares Pharma Inc
OTREXUP
methotrexate
SOLUTION;SUBCUTANEOUS204824-007Mar 24, 2016RXYesNo► Subscribe► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Tradename: OTREXUP

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,428,528 Needle assisted jet injector► Subscribe
9,750,881Hazardous agent injection system► Subscribe
9,180,259Prefilled syringe jet injector► Subscribe
6,565,553 Needle assisted jet injector► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: OTREXUP

Country Document Number Estimated Expiration
Australia2010226442► Subscribe
China1323230► Subscribe
Japan4299466► Subscribe
Australia5470499► Subscribe
Japan2015042270► Subscribe
Israel184765► Subscribe
Japan5732039► Subscribe
World Intellectual Property Organization (WIPO)0009186► Subscribe
Japan5216328► Subscribe
Japan5968976► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Chubb
Medtronic
Baxter
Cantor Fitzgerald
Boehringer Ingelheim
Farmers Insurance
Deloitte
Dow
US Department of Justice
Fuji

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot